Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q14213
UPID:
IL27B_HUMAN
Alternative names:
Epstein-Barr virus-induced gene 3 protein
Alternative UPACC:
Q14213; A0N0N2; O75269
Background:
Interleukin-27 subunit beta, also known as Epstein-Barr virus-induced gene 3 protein, plays a pivotal role in innate immunity. It forms part of the IL-27 interleukin, a cytokine with both pro- and anti-inflammatory properties. This protein is crucial in regulating T-helper cell development, suppressing T-cell proliferation, and stimulating cytotoxic T-cell activity. It also influences B-cell isotype switching and impacts various innate immune cells.
Therapeutic significance:
Understanding the role of Interleukin-27 subunit beta could open doors to potential therapeutic strategies. Its ability to regulate immune responses, combined with its antitumor and antiangiogenic activities, highlights its potential as a target for developing treatments for immune-related diseases and cancer.